Lerotinib

Lerotinib is a small-molecule drug developed by Sunshine Lake Pharma. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: Specification: 50 mg/capsule and 150 mg/capsule. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT04415853 (Study of Larotinib in Unresectable Advanced or Recurrent Oesophageal Cancer), in oesophageal cancer. The largest, NCT04415853, plans to enrol 416 participants with primary completion expected 2026-08. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.